Cargando…

Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer

BACKGROUND: Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Proteolysis targeting chimeric (PROTAC) are novel compounds that promote protein degradation by binding to an ubiquitin ligase. In this work, we explored the antitumoral activity o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noblejas-López, María del Mar, Nieto-Jimenez, Cristina, Burgos, Miguel, Gómez-Juárez, Mónica, Montero, Juan Carlos, Esparís-Ogando, Azucena, Pandiella, Atanasio, Galán-Moya, Eva M., Ocaña, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717344/ https://www.ncbi.nlm.nih.gov/pubmed/31470872 http://dx.doi.org/10.1186/s13046-019-1387-5

Ejemplares similares

Proteolysis targeting chimeras (PROTACs) in cancer therapy
por: Ocaña, Alberto, et al.
Publicado: (2020)

Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2022)

Expression of Erk5 in Early Stage Breast Cancer and Association with Disease Free Survival Identifies this Kinase as a Potential Therapeutic Target
por: Montero, Juan Carlos, et al.
Publicado: (2009)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

Neuregulin expression in solid tumors: Prognostic value and predictive role to anti-HER3 therapies
por: Ocaña, Alberto, et al.
Publicado: (2016)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Therapeutic potential of ERK5 targeting in triple negative breast cancer
por: Ortiz-Ruiz, María Jesús, et al.
Publicado: (2014)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Genetic mutational status of genes regulating epigenetics: Role of the histone methyltransferase KMT2D in triple negative breast tumors
por: Morcillo-Garcia, Sara, et al.
Publicado: (2019)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2017)

Evaluation of transcriptionally regulated genes identifies NCOR1 in hormone receptor negative breast tumors and lung adenocarcinomas as a potential tumor suppressor gene
por: Noblejas-López, María del Mar, et al.
Publicado: (2018)

Controlled Delivery of BET-PROTACs: In Vitro Evaluation of MZ1-Loaded Polymeric Antibody Conjugated Nanoparticles in Breast Cancer
por: Cimas, Francisco J., et al.
Publicado: (2020)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

Erratum: Achilles' heel of triple negative cancer
por: Ocaña, Alberto, et al.
Publicado: (2014)

A Transcriptomic Immunologic Signature Predicts Favorable Outcome in Neoadjuvant Chemotherapy Treated Triple Negative Breast Tumors
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib
por: Sánchez‐Fdez, Adrián, et al.
Publicado: (2023)

Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer
por: Montero, Juan Carlos, et al.
Publicado: (2022)

Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer
por: Sánchez-Fdez, Adrián, et al.
Publicado: (2021)

Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
por: Serrano-Oviedo, Leticia, et al.
Publicado: (2020)

Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles
por: Juan, Alberto, et al.
Publicado: (2022)

Targeting oncogenic vulnerabilities in triple negative breast cancer: biological bases and ongoing clinical studies
por: Ocana, Alberto, et al.
Publicado: (2017)

Proteolysis-targeting chimeras (PROTACs) in cancer therapy
por: Li, Xinyi, et al.
Publicado: (2022)

Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer
por: Nieto-Jimenez, Cristina, et al.
Publicado: (2020)

MEK5 promotes lung adenocarcinoma
por: Sánchez-Fdez, Adrián, et al.
Publicado: (2019)

Clinical considerations for the design of PROTACs in cancer
por: Nieto-Jiménez, Cristina, et al.
Publicado: (2022)

Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2
por: Pandiella, Atanasio, et al.
Publicado: (2015)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Transcriptomic Profiles of CD47 in Breast Tumors Predict Outcome and Are Associated with Immune Activation
por: Noblejas-López, María del Mar, et al.
Publicado: (2021)

Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications
por: Sánchez-Fdez, Adrián, et al.
Publicado: (2023)

Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis
por: Burgos, Miguel, et al.
Publicado: (2022)

Multiple myeloma: Combination therapy of BET proteolysis targeting chimeric molecule with CDK9 inhibitor
por: Lim, Su-Lin, et al.
Publicado: (2020)

Mapping Bromodomains in breast cancer and association with clinical outcome
por: Pérez-Pena, Javier, et al.
Publicado: (2019)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling
por: Cuenca-López, María D, et al.
Publicado: (2014)

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
por: He, Yonghan, et al.
Publicado: (2020)

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
por: Li, Rui, et al.
Publicado: (2022)

Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
por: Saenz, Dyana T., et al.
Publicado: (2017)

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy
por: Li, Xin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e4bjuqkhshv0utarb47bqsiid6